New reports published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlight ongoing disparities in terms of access to medicines.
The trade federation for Europe’s drugmakers said the average time to patient access is 531 days, with significant variations ranging from 126 days in Germany to 804 days in Poland.
The report highlights the degree of variability between countries, with people in some places waiting over six times longer than those in a neighboring region to receive the same treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze